Trials / Completed
CompletedNCT01768702
Safety and Efficacy of Autologous Cardiopoietic Cells for Treatment of Ischemic Heart Failure.
Efficacy and Safety of Bone Marrow-derived Mesenchymal Cardiopoietic Cells (C3BS-CQR-1) for the Treatment of Chronic Advanced Ischemic Heart Failure.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 315 (actual)
- Sponsor
- Celyad Oncology SA · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation the safety and efficacy of C3BS-CQR-1 by comparing the overall response to standard of care and C3BS-CQR-1 relative to standard of care and a sham procedure.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Injection of C3BS-CQR-1 | Injection of the C3BS-CQR-1 using the C-Cath® injection catheter. |
| BIOLOGICAL | Sham, no injection | Mimic the injection procedure trough insertion of a sham catheter. No injection actually performed |
Timeline
- Start date
- 2012-11-01
- Primary completion
- 2017-08-01
- Completion
- 2017-08-01
- First posted
- 2013-01-15
- Last updated
- 2018-06-01
Locations
35 sites across 9 countries: Belgium, Bulgaria, Hungary, Israel, Italy, Poland, Serbia, Spain, Switzerland
Source: ClinicalTrials.gov record NCT01768702. Inclusion in this directory is not an endorsement.